Abstract: Poster Presentations |

The Pharmacokinetics of Drotrecogin Alfa (Activated) In Severe Sepsis Patients Weighing >135 kg FREE TO VIEW

Rebecca L. Qualy, MS; Howard Levy, MD, PhD*; David S. Small, PhD; Darell E. Heiselman, DO; Jay S. Steingrub, MD; Christelle Darstein, MS; Ellen Mongan, MD; Richard R. Riker, MD
Author and Funding Information

Eli Lilly and Company, Indianapolis, IN


Chest. 2004;126(4_MeetingAbstracts):863S. doi:10.1378/chest.126.4_MeetingAbstracts.863S
Text Size: A A A
Published online


PURPOSE:  The FDA approved Drotrecogin alfa (activated) [DrotAA] for the reduction of mortality in adult patients with severe sepsis [sepsis with acute organ dysfunction] and a high risk of death (e.g. APACHE II score ≥25). In PROWESS, a Phase III clinical trial, limited supplies of DrotAA necessitated excluding patients whose actual body weight was >135 kg. The primary objective of this open label, Phase 4 trial was to compare the exposure to DrotAA in severe sepsis patients at high risk of death who weighed >135 kg to those who weighed <<26>135 kg. A secondary purpose was to quantify the elimination half-life of DrotAA in severe sepsis patients.

METHODS:  PROWESS inclusion/exclusion criteria were used, except patients >135 kg were also enrolled. Blood samples were taken for DrotAA steady state concentration analysis once each day and for elimination half-life analysis at 0, 15, 30, 45, 60, 90, and 120 minutes after terminating the infusion. DrotAA activity was assayed at a central laboratory. Weight-normalized clearance of DrotAA was calculated and values for patients weighing <<26>135 kg were compared with those >135 kg.

RESULTS:  Patient weight range was 59 kg –227 kg. Of 52 patients enrolled, 32 weighed <<26>135 kg, 12 weighed 136-159 kg, and 8 weighed >160 kg.

CONCLUSION:  There is no statistically significant difference in steady-state concentrations or elimination half-life of DrotAA in patients <<26>135 kg and >135 kg.

CLINICAL IMPLICATIONS:  Dosing of DrotAA should be based on actual body weight. ≤135 kg>135 kgP-valueN3220Mean weight (kg) [range]93 [59-133]158 [137-227]P=<0.001Mean BMI [range]33 [22-59]59 [41-75]P=<0.001DrotAA steady-state concentration (ng/mL) [interquartile range]60.2 [48.1-72.4]65.5 [49.9-81.0]P=0.5995DrotAA half-life (minutes) [interquartile range]19.1 [15.3-23.0]16.7 [12.2-21.1]P=0.3960

DISCLOSURE:  H. Levy, Eli Lilly and Company

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543